Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer

Alexander Dierks, Alexander Gäble, Andreas Rinscheid, Georgine Wienand, Christian H. Pfob, Malte Kircher, Johanna S. Enke, Tilman Janzen, Marianne Patt, Martin Trepel, Dorothea Weckermann, Ralph A. Bundschuh and Constantin Lapa
Journal of Nuclear Medicine March 2024, 65 (3) 432-437; DOI: https://doi.org/10.2967/jnumed.123.266741
Alexander Dierks
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Gäble
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Rinscheid
2Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgine Wienand
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian H. Pfob
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malte Kircher
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna S. Enke
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tilman Janzen
2Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Patt
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Trepel
3Internal Medicine and Oncology, Faculty of Medicine, University of Augsburg, Augsburg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorothea Weckermann
4Urology, Faculty of Medicine, University of Augsburg, Augsburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph A. Bundschuh
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constantin Lapa
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 65 no. 3 432-437
DOI 
https://doi.org/10.2967/jnumed.123.266741
PubMed 
38164586

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication September 23, 2023
  • Accepted for publication November 7, 2023
  • Published online March 1, 2024.

Article Versions

  • previous version (December 21, 2023 - 07:47).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Alexander Dierks1,
  2. Alexander Gäble1,
  3. Andreas Rinscheid2,
  4. Georgine Wienand1,
  5. Christian H. Pfob1,
  6. Malte Kircher1,
  7. Johanna S. Enke1,
  8. Tilman Janzen2,
  9. Marianne Patt1,
  10. Martin Trepel3,
  11. Dorothea Weckermann4,
  12. Ralph A. Bundschuh*,1 and
  13. Constantin Lapa*,1
  1. 1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany;
  2. 2Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, Germany;
  3. 3Internal Medicine and Oncology, Faculty of Medicine, University of Augsburg, Augsburg, Germany; and
  4. 4Urology, Faculty of Medicine, University of Augsburg, Augsburg, Germany
  1. For correspondence or reprints, contact Constantin Lapa (constantin.lapa{at}uk-augsburg.de).
  1. ↵* Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 9 Citations
  • 9 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Radiopharmaceuticals and their applications in medicine
    Siqi Zhang, Xingkai Wang, Xin Gao, Xueyao Chen, Linger Li, Guoqing Li, Can Liu, Yuan Miao, Rui Wang, Kuan Hu
    Signal Transduction and Targeted Therapy 2025 10 1
  • Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies
    Jingsong Zhang, Juskaran S. Chadha
    Cancers 2024 16 17
  • New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer
    Kévin Hébert, Paul Bodin-Cufi, Cyril Fersing, Emmanuel Deshayes
    European Urology Focus 2024 10 4
  • Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
    Alexander Gäble, Alexander Dierks, Andreas Rinscheid, Marianne Patt, Georgine Wienand, Christian H. Pfob, Malte Kircher, Kazuhito Fukushima, Ana Antić Nikolić, Johanna S. Enke, Tilman Janzen, Julie Steinestel, Hildegard Kempter, Martin Trepel, Dorothea Weckermann, Constantin Lapa, Ralph A. Bundschuh
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 3
  • Design and conduct of theranostic trials in neuro-oncology: Challenges and opportunities
    Patrick Y Wen, Matthias Preusser, Nathalie L Albert
    Neuro-Oncology 2024 26 Supplement_9
  • Preclinical Evaluation of177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy
    Caroline Foxton, Bradley Waldron, Rikke Veggerby Grønlund, Jaime (Jim) Simón, Bart Cornelissen, Edward O’Neill, Daniel Stevens
    Journal of Nuclear Medicine 2025 66 4
  • Abiraterone/docetaxel
    Reactions Weekly 2025 2048 1
  • Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial
    James Nagarajah, Hyun Kim, Luke Nordquist, Vikas Prasad, Nathaniel Scott, Daniel Stevens, Benjamin Fongenie, Joseph Osborne
    European Journal of Nuclear Medicine and Molecular Imaging 2025
  • PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study
    Lu Hou, Yanjuan Wang, Haitian Fu, Liping Chen, Chunjing Yu, Xiaoyuan Chen, Jingjing Zhang
    European Journal of Nuclear Medicine and Molecular Imaging 2025

Article usage

Article usage: December 2023 to April 2025

AbstractFullPdf
Dec 2023729335148
Jan 2024551817282
Feb 2024187501119
Mar 2024574630209
Apr 202415431190
May 20243455128
Jun 20243032416
Jul 202429016836
Aug 202422712244
Sep 20243912054
Oct 20242717469
Nov 20243917554
Dec 20242414855
Jan 20252411942
Feb 20252918536
Mar 20252414055
Apr 20252414373
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (3)
Journal of Nuclear Medicine
Vol. 65, Issue 3
March 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
Alexander Dierks, Alexander Gäble, Andreas Rinscheid, Georgine Wienand, Christian H. Pfob, Malte Kircher, Johanna S. Enke, Tilman Janzen, Marianne Patt, Martin Trepel, Dorothea Weckermann, Ralph A. Bundschuh, Constantin Lapa
Journal of Nuclear Medicine Mar 2024, 65 (3) 432-437; DOI: 10.2967/jnumed.123.266741

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
Alexander Dierks, Alexander Gäble, Andreas Rinscheid, Georgine Wienand, Christian H. Pfob, Malte Kircher, Johanna S. Enke, Tilman Janzen, Marianne Patt, Martin Trepel, Dorothea Weckermann, Ralph A. Bundschuh, Constantin Lapa
Journal of Nuclear Medicine Mar 2024, 65 (3) 432-437; DOI: 10.2967/jnumed.123.266741
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Is Long–Axial-Field-of-View PET/CT Cost-Effective? An International Health–Economic Analysis
  • Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Show more Clinical Investigation

Similar Articles

Keywords

  • prostate cancer
  • radioligand therapy
  • prostate-specific membrane antigen
  • therapeutic response
SNMMI

© 2025 SNMMI

Powered by HighWire